JDRF T1D Fund — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Seraxisseraxis.comin𝕏Sep 2023
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
William L. Rust(Executive Officer, Director, Promoter)Carole Welsch(Executive Officer)Gi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)
BoardJames N. Topper(Director)
Co-investorsMaryland TEDCOTEDCOFrazier Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.